PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression≥ 50%: selecting the best …
A Di Federico, A De Giglio, C Parisi… - Critical Reviews in …, 2021 - Elsevier
Abstract Treatment strategies for advanced NSCLC patients without driver molecular
alterations are influenced by PD-L1 expression. If PD-L1 is< 50%, the preferred upfront …
alterations are influenced by PD-L1 expression. If PD-L1 is< 50%, the preferred upfront …
Immune checkpoint inhibitors alone vs immune checkpoint inhibitors—combined chemotherapy for NSCLC patients with high PD-L1 expression: a network meta …
Y Wang, H Han, F Zhang, T Lv, P Zhan, M Ye… - British Journal of …, 2022 - nature.com
Background We indirectly compared the effects of immune checkpoint inhibitors alone (ICI)
and ICI-combined chemotherapy (chemo-ICI) in patients with non-small cell lung cancer …
and ICI-combined chemotherapy (chemo-ICI) in patients with non-small cell lung cancer …
Association between efficacy of immune checkpoint inhibitors and sex: an updated meta-analysis on 21 trials and 12,675 non-small cell lung cancer patients
C Xue, S Zheng, H Dong, X Lu, X Zhang… - Frontiers in …, 2021 - frontiersin.org
Background Mounting randomized clinical trials have proved that immune checkpoint
inhibitors (ICIs) achieved better overall survival (OS) and progression-free survival (PFS) …
inhibitors (ICIs) achieved better overall survival (OS) and progression-free survival (PFS) …
[HTML][HTML] CCTG BR34: A randomized phase 2 trial of durvalumab and tremelimumab with or without platinum-based chemotherapy in patients with metastatic NSCLC
Introduction First-line therapy for patients with metastatic NSCLC includes checkpoint
inhibitor monotherapy, dual checkpoint inhibition, or combination with chemotherapy. We …
inhibitor monotherapy, dual checkpoint inhibition, or combination with chemotherapy. We …
[HTML][HTML] Serum albumin: early prognostic marker of benefit for immune checkpoint inhibitor monotherapy but not chemoimmunotherapy
MicroAbstract Serum albumin in cancer patients is associated with clinical outcomes. In a
single-center retrospective study of 210 advanced NSCLC patients receiving immune …
single-center retrospective study of 210 advanced NSCLC patients receiving immune …
Male sex and pretreatment weight loss are associated with poor outcome in patients with advanced non-small cell lung cancer treated with immunotherapy: a …
J Jin, J Visina, TF Burns, B Diergaarde, LP Stabile - Scientific Reports, 2023 - nature.com
The influence of sex and body mass index (BMI) on the efficacy of immune checkpoint
inhibitors (ICIs) in advanced non-small cell lung cancer (NSCLC) patients remains unclear …
inhibitors (ICIs) in advanced non-small cell lung cancer (NSCLC) patients remains unclear …
[HTML][HTML] Post-progression outcomes of NSCLC patients with PD-L1 expression≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world …
A Cortellini, K Cannita, M Tiseo, DL Cortinovis… - European Journal of …, 2021 - Elsevier
Background Treatment sequencing with first-line immunotherapy, followed by second-line
chemotherapy, is still a viable option for NSCLC patients with PD-L1 expression≥ 50 …
chemotherapy, is still a viable option for NSCLC patients with PD-L1 expression≥ 50 …
[HTML][HTML] Clinical features and prognostic factors of combined small cell lung cancer: development and validation of a nomogram based on the SEER database
L Yang, Y Zhou, G Wang, D Liu, B Chen… - … lung cancer research, 2021 - ncbi.nlm.nih.gov
Background Combined small-cell lung cancer (CSCLC) refers to the simultaneous presence
of small cell lung cancer (SCLC) and any subtype of the non-small cell lung cancer …
of small cell lung cancer (SCLC) and any subtype of the non-small cell lung cancer …
Platinum Twin and Triplet Drugs Improve Chemoimmunotherapy
Y Hao, R Li, W Pan, S Tian, Y Min - Journal of Medicinal …, 2023 - ACS Publications
Several chemoimmunotherapy regimens have been approved by the US FDA, verifying the
great clinical value and potential of the strategy. However, the immunomodulatory function of …
great clinical value and potential of the strategy. However, the immunomodulatory function of …
Chemoimmunotherapy vs. Immunotherapy for First Line Treatment of Advanced Non–small Cell Lung Cancer With a PD-L1 Expression≥ 50% or≥ 90%
Background Evidence about the comparative effectiveness of chemoimmunotherapy vs.
immunotherapy alone in patients with advanced non–small cell lung cancer (aNSCLC) and …
immunotherapy alone in patients with advanced non–small cell lung cancer (aNSCLC) and …